Table 2

Univariate and multivariable analysis for relapses free period stratified by age for patients naive to systemic treatment

Characteristic

Patients < 65 years

Patients > 65 years


Univariate analysis

Multivariable analysis

Univariate analysis

Multivariable analysis


N

HR

95% CI

P

HR

95% CI

P

N

HR

95% CI

P

HR

95% CI

P


Age

.74


< 40

33

1

0


40-50

98

1.10

0.62-1.96

0


50-60

101

1.29

0.73-2.29

0


> 60

44

1.29

0.66-2.52

154


Grade

.03

0.21

.01

.29


I

31

1

1

24

1

1


II

131

1.45

0.76-2.75

1.06

0.40-2.78

74

1.73

0.66-4.58

1.30

0.48-3.58


III

75

2.17

1.12-4.20

1.54

0.58-4.11

44

3.66

1.39-9.61

2.01

0.70-5.75


Histological type

.54

.53


Ductal

223

1

124

1


Other

15

1.24

0.63-2.45

18

0.74

0.30-1.87


Tumor stage

< .001

0.05

.03

.90


pT1

137

1

1

59

1

1


pT2

109

1.66

1.16-2.37

1.60

1.01-2.55

71

2.23

1.22-4.09

1.16

0.56-2.40


pT3/4

22

2.73

1.57-4.76

2.04

1.07-3.88

18

2.11

0.82-5.45

1.23

0.42-3.63


Nodal stage

< .001

< 0.001

< .001

< .001


Negative

204

1

1

109

1

1


Positive

69

4.25

3.02-5.99

4.44

2.89-6.82

36

3.94

2.28-6.82

3.33

1.77-6.24


ER status

.59

.22


Negative

87

1

40

1


Positive

126

0.90

0.66-1.32

95

1.53

0.78-2.98


PgR status

.78

.78


Negative

84

1

55

1


Positive

123

0.95

0.64-1.40

81

1.08

0.61-1.92


HER2 status

.26

.05


Negative

143

1

105

1


Positive

19

1.44

0.76-2.71

4

0.05

0.00-23.3


ALDH1 status

.01

0.02

.14


Negative

77

1

1

63

1


Positive

116

1.75

1.14-2.68

1.71

1.09-2.68

61

0.64

0.35-1.16


Abbreviations: N number of patients; HR hazard ratio; ER estrogen receptor; PgR progesterone receptor; HER2 human epidermal growth factor receptor 2; ALDH1 aldehyde dehydrogenase 1

Mieog et al. BMC Cancer 2012 12:42   doi:10.1186/1471-2407-12-42

Open Data